MGCD treatment inhibited HDACs, enhanced miR‐133a, and decreased the levels of α‐SMA and COL1α‐2, leading to reduced renal fibrosis/remodeling and lowered BP in the mutant animals (Figure 10). The gene discussed is ACTA1; the disease is renal fibrosis.